NovaMedica is expanding its portfolio of drugs for the treatment of diseases of the central nervous system

DIEZO^® 500 is indicated for use in the acute period of ischemic stroke (as part of combination therapy), in the recovery period after ischemic or hemorrhagic stroke, as well as for cognitive and behavioral disorders caused by degenerative and vascular diseases of the brain.

This addition to the portfolio will allow NovaMedica to expand the opportunities for neurologists and general practitioners to prescribe modern, effective nootropic therapy in a convenient tablet dosage form, which is more familiar for patients. The drug is manufactured from a high-quality active pharmaceutical ingredient at the facilities of the NovaMedica Innotech site in the Russian Federation, certified according to the EAEU GMP requirements, which will ensure uninterrupted supplies of this much-needed product.

Elena LITVINOVA, CEO of NovaMedica:

“NovaMedica is consistently implementing a strategy to expand its portfolio of drugs for the treatment of diseases of the central nervous system to provide Russian patients and the medical community with advanced therapeutic solutions in the growing CNS segment. Medicines in the company's portfolio are actively used to treat a wide range of indications from Alzheimer's type dementia, schizophrenia, and migraine to pain syndrome and sleep disorders. It is important to note that NovaMedica continues to develop its portfolio and plans to bring new drugs to the market in its focus therapeutic area, i.e. CNS.”  

Marina PUTILINA, Doctor of Medical Sciences, Professor of the Department of Neurology, Faculty of Postgraduate Education, Pirogov Russian National Research Medical University:

“The availability of different dosage forms (solution, injection) allows the use of Citicoline in various groups of patients, including those with difficulty swallowing. However, the appearance of the tablet form will increase therapy compliance in patients with intolerance to liquid forms and inability to take long-term injection courses."  

According to IQVIA, in 2023, the commercial nootropics market in Russia exceeded 21 billion rubles in sales with an annual increase of +8%. Citicoline products have a market share of 20% with a growth trend of up to +10% annually over the 2024-2027 horizon.